HS
NRIX icon

HighVista Strategies’s Nurix Therapeutics NRIX Stock Holding History

HighVista Strategies’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.51M Buy
+226,546
New +$3.76M 0.97% 31
2022
Q1 		– Sell
-18,796
Closed -$544K – 92
2021
Q4 		$544K Hold
18,796
– – 0.43% 64
2021
Q3 		$563K Sell
18,796
-10,584
-36% -$327K 0.37% 70
2021
Q2 		$779K Buy
29,380
+10,158
+53% +$298K 0.55% 55
2021
Q1 		$598K Buy
+19,222
New +$727K 0.44% 59

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

HighVista Strategies's NRIX Position: Q1 2026 in Review

HighVista Strategies opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 226,546 shares worth $3.51M. The stake represents 0.97% of the portfolio and ranks #31 among its holdings. This is a return to the name: HighVista Strategies previously reported a position in NRIX as recently as Q4 2021.

HighVista Strategies first reported a position in NRIX in Q1 2021 and has held it in 5 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • HighVista Strategies held 226,546 shares of Nurix Therapeutics worth $3.51M as of Q1 2026.
  • Nurix Therapeutics was a new HighVista Strategies position in Q1 2026.
  • Nurix Therapeutics made up 0.97% of HighVista Strategies's portfolio in Q1 2026, its #31 holding.
  • HighVista Strategies first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.